News
Displaying 61–70 of 551
-
Foundation Fighting Blindness Celebrates 20 Years of VisionWalk
Foundation NewsVisionWalk has been uniting communities across the country for 20 years, all while raising awareness and funding research driving treatments and cures for blinding diseases.
-
Harriet Finkelstein, Foundation Angel, Passes Away
Foundation NewsThough unaffected by vision loss, she brought great passion to driving the Foundation’s mission.
-
Foundation News
The free, online event at 7 p.m. ET on March 13, 2025, will feature presentations from Christine Kay, MD, Vitreoretinal Associates in Gainesville, Florida, and Thomas Mendel, MD, PhD, Ohio State University Wexner Medical Center.
-
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
Research NewsThe Foundation is a founding investor in Atsena.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
Research News
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
Foundation News
ARPA-H award establishes multi-disciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation.
Goal to bring light to those who are blind through first-ever successful vision recovery in six whole eye transplants in humans by 2030.
-
Research News
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
